Burning Rock Biotech Limited (NASDAQ:BNR) Short Interest Down 6.6% in December

Burning Rock Biotech Limited (NASDAQ:BNR) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 60,500 shares, a drop of 6.6% from the December 15th total of 64,800 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily volume of 26,300 shares, the days-to-cover ratio is presently 2.3 days.

Burning Rock Biotech Trading Up 3.8 %

BNR stock traded up $0.25 on Friday, reaching $6.75. 308 shares of the company were exchanged, compared to its average volume of 7,089. Burning Rock Biotech has a 12 month low of $2.62 and a 12 month high of $9.80. The stock’s fifty day moving average price is $6.15 and its 200 day moving average price is $5.29.

Institutional Investors Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC bought a new stake in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned 0.10% of Burning Rock Biotech at the end of the most recent quarter. Institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.